Publications by authors named "Q Campbell-Hewson"
We profiled a large heterogenous cohort of matched diagnostic-relapse tumour tissue and paired plasma-derived cell free DNA (cfDNA) from patients with relapsed and progressive solid tumours of childhood. Tissue and cfDNA sequencing results were concordant, with a wider spectrum of mutant alleles and higher degree of intra-tumour heterogeneity captured by the latter, if sufficient circulating tumour-derived DNA (ctDNA) was present. Serial tumour sequencing identified putative drivers of relapse, with alterations in epigenetic drivers being a common feature.
View Article and Find Full Text PDFImportance: In poor-prognosis children's cancers, new therapies may carry fresh hope for patients and parents. However, there is an absolute requirement for any new therapy to be properly evaluated to fulfill scientific, regulatory, and reimbursement requirements. Randomized clinical trials (RCTs) are considered the gold standard, but no consensus exists on how and when they should be deployed to best meet the needs of all stakeholders.
View Article and Find Full Text PDFImportance: The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines.
Objective: To evaluate whether the addition of lenvatinib to IE (LEN-IE) improves outcomes in children and young adults with relapsed or refractory osteosarcoma.
Design, Setting, And Participants: The OLIE phase II, open-label, randomized clinical trial was conducted globally across Europe, Asia and the Pacific, and North America.
Article Synopsis
- Osteosarcoma and Ewing sarcoma are challenging bone tumors primarily affecting younger individuals, with low survival rates even after various treatment approaches.
- Current research on targeted therapies and immunotherapies has been ineffective, highlighting the need for a deeper understanding of the tumor biology and the immune microenvironment.
- A new Europe-wide framework for systematic sampling and analysis of patient samples has been proposed, supported by international consortia aiming to set guidelines that will enhance research collaboration and ultimately improve treatment outcomes.
Article Synopsis
- A phase Ib study investigated the safety, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of regorafenib when combined with vincristine and irinotecan for treating kids with relapsed/refractory solid tumors, primarily rhabdomyosarcoma.
- The study involved 21 patients, determining the MTD/RP2D of regorafenib at 82 mg/m2 when given sequentially; adverse effects mostly included severe blood-related issues, with varying levels of response observed in tumors.
- Findings suggest that regorafenib can be safely combined with vincristine and irinotecan in pediatric settings, showing promising clinical activity for certain types of tumors.